Does CJC-1295 work?
Partly: a few small trials in healthy volunteers, lasting at most 49 days, checking blood tests only.
Two randomized placebo-controlled dose-ranging trials and one overnight sampling study, all in healthy adults, show CJC-1295 raises growth hormone and IGF-1 for days after a single injection. The largest enrolled a few dozen volunteers, measured hormone levels only, and lasted 49 days. No trial has measured muscle, fat, recovery or ageing outcomes, which are the uses it is sold for, so the grade is B on surrogate endpoints only. 12
Teichman and colleagues ran two randomized, placebo-controlled, double-blind trials in healthy adults aged 21 to 61. After one injection, mean GH rose 2- to 10-fold for six days or more. IGF-1 rose 1.5- to 3-fold for 9 to 11 days. The estimated half-life was 5.8 to 8.1 days. After repeated injections over several weeks, IGF-1 stayed above baseline for up to 28 days. It also built up. No serious adverse reactions occurred. 1
Ionescu and Frohman ran a separate study in healthy men. It confirmed that GH pulses were preserved. IGF-1 rose by about 45% one week after a single injection. 2
Evidence checklist
- Randomised controlled trial Two placebo-controlled dose trials
- Human study over 100 people Trials enrolled a few dozen volunteers
- More than one research group Main trials from one group plus one study
- Clinical outcomes, not surrogate markers GH and IGF-1 levels only
- Human safety data beyond case reports Short trials; nothing beyond 49 days
More on CJC-1295
Citations
- Teichman 2006, J Clin Endocrinol Metab: prolonged GH and IGF-1 stimulation by CJC-1295 in healthy adults pubmed.ncbi.nlm.nih.gov
- Ionescu 2006, J Clin Endocrinol Metab: pulsatile GH secretion persists during CJC-1295 stimulation pubmed.ncbi.nlm.nih.gov
- Jette 2005, Endocrinology: hGRF(1-29)-albumin bioconjugates, identification of CJC-1295 pubmed.ncbi.nlm.nih.gov
- 2026, Front Endocrinol: performance-enhancing peptides modulating the GH-IGF-1 axis, review pubmed.ncbi.nlm.nih.gov
- FDA: certain bulk drug substances for use in compounding may present significant safety risks fda.gov
- 1994, J Clin Endocrinol Metab: D-Ala2 GHRH(1-29) half-life and clearance in normal men pubmed.ncbi.nlm.nih.gov
- Lexology, September 2024: FDA removes certain peptide bulk drug substances from Category 2 lexology.com
- FDA briefing document, Pharmacy Compounding Advisory Committee, December 2024 fda.gov
Reference information only, not medical advice. Drawn from the CJC-1295 article, fact-checked against the cited sources. No dosing anywhere on this site.